Ann Arbor’s Genomenon Inc. Closes $20M Funding Round

Genomenon Inc., an artificial intelligence (AI)-driven genomics company based in Ann Arbor, has completed a $20 million Series B financing round led by Farmington Hills-based Beringea U.S.
127
Biotechnology Molecular Engineering DNA Genetic Manipulation
Farmington Hills’ Beringea U.S. led the $20 million Series B financing round of Genomenon Inc. in Ann Arbor. // Stock Photo

Genomenon Inc., an artificial intelligence (AI)-driven genomics company based in Ann Arbor, has completed a $20 million Series B financing round led by Farmington Hills-based Beringea U.S.

The funds will be used to expand the company’s commercial operations and the development of its genomic data hub, which serves genetic testing labs, hospitals, pharmaceutical, and biopharma companies.

Genomenon leverages AI to organize the world’s genomic knowledge and put it at the fingertips of doctors and clinicians to diagnose patients with rare and genetic disease and cancer. It also assists researchers with creating precision medicine targeted at molecular drivers of disease.

“Coming on the heels of a successful 2021 where the company once again more than doubled its revenue and customer base, Genomenon will use the new funds to grow its commercial team to reach new customers around the world,” says Mike Klein, CEO of Genomenon. “Our AI-driven technology enables genomic insights to support clinicians in patient diagnosis and scientists developing precision medicines.”

The company’s Mastermind Genomic Search Engine is used by more than 1,000 genetic testing labs and hospitals worldwide to provide clinical insight into the scientific literature on genomic data.

Its Prodigy Genomic Landscapes are used by top pharma and biopharma companies to deepen understanding of the genetic drivers and clinical attributes of any genetic disease, from rare disorder to cancer. These datasets enable pharma companies to accelerate target discovery, identify genetic biomarkers for clinical trial stratification, and develop companion diagnostics for regulatory approval.

“As proliferation of sequencing drives exponential growth in the new frontier of genomic informed precision medicine, Genomenon’s AI driven technology platform is the ideal solution to bring life changing therapies to patients while enabling Pharma to more efficiently discover and develop new targeted therapies,” says Michael Gross, managing director at Beringea. “We are excited to partner with Genomenon’s world-class management team to continue to drive industry wide adoption of this transformational platform.”

Facebook Comments